149 related articles for article (PubMed ID: 30335819)
1. Prognostic value of ErbB2/HER2 in human meningiomas.
Arnli MB; Winther TL; Lydersen S; Torp SH
PLoS One; 2018; 13(10):e0205846. PubMed ID: 30335819
[TBL] [Abstract][Full Text] [Related]
2. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study.
Loussouarn D; Brunon J; Avet-Loiseau H; Campone M; Mosnier JF
Hum Pathol; 2006 Apr; 37(4):415-21. PubMed ID: 16564915
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S
J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338
[TBL] [Abstract][Full Text] [Related]
6. Her2neu amplification associates with Co-deletion 1p/14q in recurrent meningiomas.
Hamilton BO; Sy JS; Megyesi JF; Ang LC
Can J Neurol Sci; 2013 May; 40(3):361-5. PubMed ID: 23603172
[TBL] [Abstract][Full Text] [Related]
7. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
[TBL] [Abstract][Full Text] [Related]
8. Genetic changes with prognostic value in histologically benign meningiomas.
Barbera S; San Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Roldan P; Gonzalez-Darder J; Cerda-Nicolas M; Lopez-Gines C
Clin Neuropathol; 2013; 32(4):311-7. PubMed ID: 23442303
[TBL] [Abstract][Full Text] [Related]
9. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas.
Pravdenkova S; Al-Mefty O; Sawyer J; Husain M
J Neurosurg; 2006 Aug; 105(2):163-73. PubMed ID: 17219818
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
11. Correlation between cytogenetic and clinical findings in 215 human meningiomas.
Steudel WI; Feld R; Henn W; Zang KD
Acta Neurochir Suppl; 1996; 65():73-6. PubMed ID: 8738501
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
13. Is the Simpson Grading System Applicable to Estimate the Risk of Tumor Progression After Microsurgery for Recurrent Intracranial Meningioma?
Schipmann S; Schwake M; Sporns PB; Voß KM; Sicking J; Spille DC; Hess K; Paulus W; Stummer W; Brokinkel B
World Neurosurg; 2018 Nov; 119():e589-e597. PubMed ID: 30081236
[TBL] [Abstract][Full Text] [Related]
14. Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence.
Urbschat S; Rahnenführer J; Henn W; Feiden W; Wemmert S; Linsler S; Zang KD; Oertel J; Ketter R
Int J Oncol; 2011 Dec; 39(6):1601-8. PubMed ID: 21922133
[TBL] [Abstract][Full Text] [Related]
15. WHO grade 1 meningioma recurrence: Are location and Simpson grade still relevant?
Gallagher MJ; Jenkinson MD; Brodbelt AR; Mills SJ; Chavredakis E
Clin Neurol Neurosurg; 2016 Feb; 141():117-21. PubMed ID: 26780494
[TBL] [Abstract][Full Text] [Related]
16. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma.
Hao S; Smith TW; Chu PG; Liu Q; Ok CY; Woda BA; Lu D; Lin P; Wang SA; Dresser K; Rock KL; Jiang Z
Arch Pathol Lab Med; 2011 Aug; 135(8):1032-6. PubMed ID: 21809995
[TBL] [Abstract][Full Text] [Related]
17. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of rhabdoid meningiomas: report of 12 cases and a systematic review of the literature.
Zhou Y; Xie Q; Gong Y; Mao Y; Zhong P; Che X; Jiang C; Huang F; Zheng K; Li S; Gu Y; Bao W; Yang B; Wu J; Wang Y; Chen H; Xie L; Zheng M; Tang H; Wang D; Zhu H; Chen X
World Neurosurg; 2013; 79(5-6):724-32. PubMed ID: 22902360
[TBL] [Abstract][Full Text] [Related]
19. Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.
Ke HL; Ke RH; Li ST; Li B; Lu HT; Wang XQ
J Neurooncol; 2013 Jun; 113(2):327-32. PubMed ID: 23525949
[TBL] [Abstract][Full Text] [Related]
20. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
